Quantcast

Latest C-Met Stories

2010-09-14 00:54:32

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model.

2010-06-17 03:10:00

WAYNE, N.J., June 17 /PRNewswire/ -- Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

2010-04-30 07:59:00

FREISING-WEIHENSTEPHAN, Germany, April 30, 2010 /PRNewswire/ -- Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin(R) compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model.

2009-06-02 08:46:05

A gene well known to stop or suppress cancer plays a role in cancer stem cells, according to a new study from the University of Michigan Comprehensive Cancer Center.

2009-06-02 08:42:09

Cancer develops when cells known as cancer stem cells begin to divide in an uncontrolled manner. Researchers from the University of Michigan Comprehensive Cancer Center have identified roles for the gene PTEN, which is already well known for its ability to suppress tumor growth, and for several pathways linked to PTEN in the growth of cells that give rise to breast cancer.

2009-05-19 06:00:00

INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Florida, May 29 through June 2, 2009. The presentation for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows:...

2009-04-16 08:34:00

Early Research Suggests that Understanding the Fundamental Mechanism of Angiogenesis is More Complicated Than Understanding the Function of VEGF - A Amgen Launches Angiogenesis Website THOUSAND OAKS, Calif., April 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents will be presented at the 2009 American Association for Cancer Research (AACR) Annual Meeting in Denver between April 18-22, 2009.

2009-03-17 07:00:00

INDIANAPOLIS, March 17 /PRNewswire/ -- Semafore Pharmaceuticals, Inc.

2008-10-23 09:00:38

Exelixis, a development-stage biotechnology company, has reported positive interim data from a Phase I dose-escalation trial of XL765, a small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

2008-10-22 09:00:42

MethylGene Inc. (TSX: MYG) today disclosed preclinical biomarker data for its kinase inhibitor, MGCD265, in a poster session at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva.


Word of the Day
metagrabolized
  • totally perplexed and mixed up.
The word 'metagrabolized' is also spelled 'metagrobolized'.
Related